Invalidity dossier
US 4826973
Delta form of aztreonam and preparation thereof
Current assignee: ER Squibb and Sons LLC
Added 9/23/2026, 7:57:52 PM
Active provider: DeepSeek · deepseek-flash
Patent summary
Title, assignee, inventors, filing/issue dates, abstract, and a plain-language overview of the claims.
US 4,826,973 — Delta Form of Aztreonam and Preparation Thereof
Bibliographic data (from supplied text):
- Patent number: US 4,826,973 A
- Application number: US06/807,374; filed 1985-12-10
- Publication/grant date: 1989-05-02; anticipated expiration 2006-05-02
- Priority date: 1984-07-20 (stated as an assumption)
- Inventors: Neal G. Anderson; Carl F. Anderson
- Original and current assignee: ER Squibb and Sons LLC (assignment recorded 1989-02-10 to E. R. Squibb & Sons, Inc., a Delaware corporation)
- Legal status: Expired – Lifetime (stated as an assumption, not a legal conclusion)
Purpose and scope (plain language, per the supplied text): The patent concerns a delta crystalline form of aztreonam and methods of preparing it. The claims and description reference 2-amino-4-thiazolyl, acetic acid, imino, and primary amino chemical groups; aztreonam itself is identified as antibiotic SQ 26917. The disclosed preparation methods use solvents and reagents including dimethylformamide, dimethylsulfoxide, trifluoroacetic acid, trichloroacetic acid, chlorinated hydrocarbons, water, methanol, ethanol, acetone, anisole, tetrahydrofuran, ethyl acetate, and diethyl ether. The text mentions process steps such as solvolysis, cooling, recrystallization, slurrying, filtration, drying (including vacuum drying), and characterization by powder X-ray diffraction, Karl Fischer titration, gas chromatography, and high-performance liquid chromatography. Reaction-mixture and isolation handling are also referenced.
What the excerpt does not establish: The supplied text is heavily truncated ("[Excerpt only; consult the source for omitted text]"). It does not reproduce the actual numbered claims, the written description, examples, tables, or figures, so the precise metes and bounds of the claimed invention, the specific delta-form characterization data (e.g., X-ray diffraction peaks), and the exact synthetic schemes cannot be verified from this excerpt. It also provides no information on litigation, ownership transfers beyond the recorded assignment, validity, or prior art beyond keyword indexing. The abstract and claim text are not included.
Generated 10/1/2026, 9:41:41 PM
Cases on file (0)
Specific litigation cases in our database that name US patent 4826973. The free-form analysis below may also discuss cases beyond this list.
No cases on file mention this patent. Upload a CSV or add a case manually in Admin → Manage litigation cases.
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Proceedings on file (0)
All PTAB activity →AIA trial proceedings (IPR / PGR / CBM) filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced from the USPTO Open Data Portal and refreshed every six hours; each proceeding number deep-links to the PTAB E2E docket.
No PTAB proceedings on file. This patent has not been challenged via IPR, PGR, or CBM. The absence is itself a signal — well-asserted patents eventually attract IPRs. The LLM analysis below may surface filings the ODP feed hasn’t indexed yet.
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Assignment history
Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.
Prior art
Earlier patents, publications, and products that may anticipate or render the claims unpatentable.
Obviousness
Combinations of prior art that suggest the claimed invention would have been obvious under 35 U.S.C. § 103.
Extensions
Patent term adjustments, term extensions, continuations, divisionals, family members, and expiration dates.
Derivative works
Defensive disclosure: derivative variations of each claim designed to render future incremental improvements obvious or non-novel.